bearish
[Zai LAB (ZLAB US) Target Price Change]: Demonstrating Directionally Business Model to Profit
281 Views11 May 2023 16:10
Zai Lab (ZLAB) reported C1Q23 top line in-line with our estimate but operating/net loss much smaller than our estimate due to cut in R&D spending as well as higher interest income.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Blue Lotus Research Institute
China growth and global non-US Internet equities
Price Chart(Sign Up to Access)
- ZaiLab's DLL3 ADC Is a Major Positive, but the Market Over-Reacted to Its Prospects26 Oct 2024
- [Zai LAB (ZLAB US, SELL, TP US$20) TP Change]: Two Positive News Drove up 2024 Growth Target14 Dec 2023
- [Blue Lotus Innovative Drugs Sector Update]: Biotech-Biopharma Ecosystem Is Coming of Age in China12 Jul 2023
- [Zai LAB (ZLAB US) Earnings Review]: Pretty Much the Same…Maintain SELL03 Mar 2023
- Zai LAB (ZLAB.US/9688.HK)：TTF Is Not a Done Deal, Both China and Globally11 Jan 2023
- Autonomous Driving- The Tesla Delusion06 Apr 2018
x